Gemifloxacin

2.1. Fluoroquinolones Sources of fluoroquinolones were: Bayer AG moxifloxacin ; , Bristol-Myers Squibb gatifloxacin ; , Glaxo-Smith Kline gemifloxacin ; , Janssen-Ortho levofloxacin ; . All compounds were prepared in accordance with manufacturer's specifications instructions. 2.2. Susceptibility determination Minimal inhibitory concentrations were determined by microbroth dilution with interpretation in accordance with NCCLS guidelines [26]. Briefly, MuellerHinton broth containing two-fold concentration increments of antimicrobial agents was added to 96-well microdilution trays. Test organism suspension equal to a 0.5 McFarland standard was further diluted and added to the trays to achieve a final inoculum of 5 105 cfu ml. Inoculated plates were incubated for 1824 h at 35 ambient air. For microbroth dilution, the minimal inhibitory concentration was recorded as the lowest dilution showing no growth. Staphylococcus aureus isolates were screened for susceptibility to methicillin by plating on to MuellerHinton agar plates containing 6 g ml oxacillin. 2.3. Nucleotide sequence analysis Recovered colonies were subsequently screened for the mecA gene using an in house polymerase chain reaction assay utilizing the following primers: mec-1: 5 -GGG ATC ATA GCG TCA TTA TTC-3 and mec-2: 5 -AAC GAT TGT GAC ACG ATA GCC-3 . 2.4. MPC measurements The method for measuring MPC is a modification of that previously described [24]. Briefly, 23 tryptic soy agar with 5% sheep blood plates per organism were inoculated to produce confluent growth and then incubated overnight 1824 h at 3537 C in ambient air ; . The next day, the contents of the plates were transferred to 100 ml of MuellerHinton broth and incubated overnight as described. The following day a total of 100 l containing 1010 cfu was inoculated to tryptic soy agar plates containing antimicrobial agent. Drug containing plates were prepared in-house and used within seven days of preparation. A range of seven drug concentrations were inoculated with the lowest drug concentration being the MIC. Inoculated plates were incubated for 24 h as described and then examined for growth. Plates were re-incubated as described for an additional 24 h and then re-examined. Colonies growing on plates containing drug at concentrations exceeding the susceptibility breakpoint or 3 doubling dilutions above the MIC were subcultured to tryptic soy agar plates containing the same drug concentration as the plate they were recovered from. Plates that had a film making it difficult to identify indi.
147; compound ” shall mean the form of gemifloxacin mesylate having the molecular formula. Wise, Michael -1687, English Baroque A Catch on the Midnight Cats Awake, Put on Thy Strength Old Chiron Prepare ye the way of the Lord Ways of Zion Do Mourn, The Witt, Franz Xaver 1834-1888, German Romantic At te levavi Gloria et honore Improperium expectavit cor meum Libera me Domine Meditabor O salutaris hostia Perfice gressus meos Quis ascendit in montem Domini? Sperent in te omnes Te Joseph celebrent Verbum supernum prodiens Witzka, Carl Bonaventura 1768-1848, German Romantic Gaudent in coelis Wolf, Hugo Austrian Romantic Aufblick Ergebung Verborgenheit Verschwiegene Liebe Wood, Charles 1866-1926, English Early 20th Blessed be that Maid Marie Ding dong! merrrily on high Evening Service in D Major Evening Service in E Flat Major, number 1 Evening Service in E Flat Major, number 2 Evening Service in E Major Evening Service in E Minor Great Lord of Lords Hail, Gladdening Light Jesu, the Very Thought is Sweet Jesu, the Very Thought is Sweet Music When Soft Voices Die O for a lay! O Thou, the Central Orb Oculi omnium This joyful Eastertide Twas in the Year that King Uzziah Died Woodward, G. R. 1848-1934, English Early 20th Up! Good Christen folk and listen Wooldridge, H. E. Renaissance Hark! How All the Welkin Rings Maria, Jungfrau rein O Maria, meine Hilfe Tod Jesu Zaninetti, Jos Ecce panis Ecce panis angelorum Fuente pura Ofrenda Seor Sacramentado Tantum ergo Zebley, John Jr. O Lord, Abide with Me Zelenka, Jan Dismas Laudate Dominum Zespedes, Juan Garcia de Convidando esta la noche Zielenski, Mikolaj Benedicamus Deum coeli Magnificat a 12 Viderunt omnes fines terrae Zimmer, J. Lateinische Messe fr Mnnerchor Zingarelli, Niccolo Zipoli, Domenico O Daliso, da quel d che partisti Zuccari, Francesco M. Dextera Domini Zuccaro, Ilaria Ein Kind geborn zu Betlehem O salutaris hostia Singet dem Herrn Were You There Zucchinetti, Giovanni Bernardo Improperium Tenuisti manum Zumstein, Louis D. Praise Ye the Lord Zwyssig, Peter Josef Adoro te Anima Christi Ave Maria O salutaris hostia. Interaction between stress and cannabinoid effects. The results of these studies indicate that.

FULL TEXT OF ALL JOURNAL ARTICLES ON THE WORLD WIDE WEB Access to the complete text of the Journal on the Internet is free to all subscribers. To use this Web site, subscribers should go to the Journal's home page nejm ; and register by entering their names and subscriber numbers as they appear on their mailing labels. After this one-time registration, subscribers can use their passwords to log on for electronic access to the entire Journal from any computer that is connected to the Internet. Features include a library of all issues since January 1993, a full-text search capacity, a personal archive for saving articles and search results of interest, and free software for downloading articles so they can be printed in a format that is virtually identical to that of the typeset pages. Twenty-one clinical isolates of Streptococcus pneumoniae showing reduced susceptibility or resistance to fluoroquinolones were characterized by serotype, antimicrobial susceptibility, and genetic analyses of the quinolone resistance-determining regions QRDRs ; of gyrA, gyrB, parC, and parE. Five strains were resistant to three or more classes of antimicrobial agents. In susceptibility profiles for gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin, 14 isolates had intermediate- or highlevel resistance to all fluoroquinolones tested except gemifloxacin no breakpoints assigned ; . Fluoroquinolone resistance was not associated with serotype or with resistance to other antimicrobial agents. Mutations in the QRDRs of these isolates were more heterogeneous than those previously reported for mutants selected in vitro. Eight isolates had amino acid changes at sites other than ParC S79 and GyrA S81; several strains contained mutations in gyrB, parE, or both loci. Contributions to fluoroquinolone resistance by individual amino acid changes, including GyrB E474K, ParE E474K, and ParC A63T, were confirmed by genetic transformation of S. pneumoniae R6. Mutations in gyrB were important for resistance to gatifloxacin but not moxifloxacin, and mutation of gyrA was associated with resistance to moxifloxacin but not gatifloxacin, suggesting differences in the drug-target interactions of the two 8-methoxyquinolones. The positions of amino acid changes within the four genes affected resistance more than did the total number of QRDR mutations. However, the effect of a specific mutation varied significantly depending on the agent tested. These data suggest that the heterogeneity of mutations will likely increase as pneumococci are exposed to novel fluoroquinolone structures, complicating the prediction of cross-resistance within this class of antimicrobial agents. Streptococcus pneumoniae is the leading cause of community-acquired pneumonia in the United States and a major cause of meningitis and otitis media 44 ; . For decades, the treatment of pneumococcal infections relied primarily on the use of -lactam and macrolide agents. However, with the emergence and spread of penicillin- and multidrug-resistant MDR ; strains 44, 46 ; the development of new antimicrobial agents has become essential in providing effective treatment options. Fluoroquinolones are broad-spectrum antimicrobial agents introduced in the 1980s. The early fluoroquinolones, such as ciprofloxacin and ofloxacin, had limited activity against S. pneumoniae 48 ; . Newer fluoroquinolones, with enhanced activity against pneumococci and other gram-positive organisms, have been developed and will provide useful alternative therapies for pneumococcal infections as long as the development of resistance can be minimized and controlled. However, with increased use of fluoroquinolone therapy, resistant pneumococci have emerged and treatment failures have been documented 5, 31, 40, ; . Although current data indicate that the incidence of resistant strains is low, recent reports have noted an increase in the prevalence of fluoroquinolone-resistant pneumococci 8, 21; C. Garci a-Rey, L. Aguilar, F. Baquero, and the Spanish Surveillance Group for Respiratory Pathogens, Letter, Antimicrob. Agents Chemother. 44: 3481 3482, ; . Resistance to fluoroquinolones is acquired in stepwise fashion with the introduction of chromosomal mutations that alter the target proteins, DNA gyrase and topoisomerase IV, or decrease intracellular drug accumulation by active drug efflux. DNA gyrase, an A2B2 tetramer encoded by gyrA and gyrB, introduces negative supercoils in DNA to relieve the topological stress generated during DNA replication and transcription 45, 51 ; . Topoisomerase IV, a C2 2 tetramer encoded by parC and parE, is important in decatenation and partitioning of daughter chromosomes following DNA replication 1, 30 ; . These activities require the introduction and repair of doublestrand breaks in the chromosomal DNA by both enzymes. The primary target of a fluoroquinolone, either gyrase or topoisomerase IV, depends on the chemical and structural properties of the agent. High-level resistance is associated with point mutations in discrete regions of the gyrase and topoisomerase IV genes, designated as the quinolone resistance-determining regions QRDRs ; 50 ; . Early studies of these mutations were based on the analysis of mutants selected in vitro on subinhibitory concentrations of ciprofloxacin 25, 33, 36 ; . The resulting mutations occurred most frequently in the codons for ParC S79 and GyrA S81. Only recently, however, have studies included analysis of gyrB and parE 10, 20, 28, ; , although mutations in these loci have been described as rare and insignificant 26, 27, 47 ; . In this study, recent clinical isolates of fluoroquinoloneresistant pneumococci from the United States were analyzed to determine the molecular basis of resistance, the activity of newer fluoroquinolones against the mutant strains, and the and gemtuzumab.

Correspondence: Jos Mara Lemus Gallego, Department of Analytical Chemistry and Food Technology, Facultad de Ciencias Qumicas, Universidad de Castilla-La Mancha, 13071 Ciudad Real, Spain. Phone: + 34 926 295 ext. 3443. Fax: + 34 9 E-mail: JoseMaria.Lemus uclm . Abbreviations: PRE, Prednisolone; PHE, Phenylephrine; NAP, Naphazoline; PLS, Partial Least Square Regression; PCR, Principal Components Regression; PRESS, Prediction Error Sum of Squares; RSMD, Root Mean Squares Difference; R 2, Squares of Correlation Coefficients; REP, Relative Error of Prediction.
Number of subjects percent ; Pancreatitis Elevated serum lipase level Peripheral neuropathy Rash Central nervous system effects Gastrointestinal effects Hepatic effects Hematologic effects 18 ; 99 10.1 ; 154 15.7 ; 113 11.5 ; 122 12.4 ; 68 6.9 ; 62 6.3 ; 34 3.5 ; 7 4.5 ; 23 14.8 ; 41 26.5 ; 22 14.2 ; 18 11.6 ; 10 6.5 ; 12 7.7 ; 3 1.9 ; 6 3.9 ; 20 12.9 ; 29 18.7 ; 17 11.0 ; 22 14.2 ; 20 12.9 ; 16 10.3 ; 7 4.5 ; 1 0.6 ; 13 8.4 ; 10 6.5 ; 16 10.3 ; 20 12.9 ; 6 3.9 ; 4 2.6 ; 8 5.2 ; 1 0.6 ; 9 5.8 ; 16 10.3 ; 16 10.3 ; 21 13.5 ; 11 7.1 ; 7 4.5 ; 6 3.9 ; 2 1.1 ; 20 11.2 ; 42 23.6 ; 19 10.7 ; 16 9.0 ; 11 6.2 ; 14 7.9 ; 3 1.7 ; 1 0.5 ; 14 7.7 ; 16 8.8 ; 23 12.6 ; 25 13.7 ; 10 5.5 ; 9 4.9 ; 7 3.8 and gemzar.

3 consequently, gemifloxacin and supplements containing magnesium should not be taken at the same time and gentian. Oral admlnlstration Endrin ishigtrly toxic whengivenby the oral route andismore acutely toxic to mammals than its stereoisomerdieldrin WHO, 1989 ; , with an acuteoralLDroof7.5-17.8 mg kgbodyweight Iable 21 ; , compared with 50-60 mg kg for dieldrin. There appearsto be a sex-dependent sensitivity to the acute effects of endrin, female animals being more sensitive than males. A species-dependent sensitivity has also beenreported, monkeys and catsbeing more susceptible than mice andrats. Signs of intoxication may include increased initability and tremor, followed by tonic-clonic convulsions, ataxia, dyspnoea, gasping, and cyanosis. Convulsions usually occur 3Od ; min after an oral dose, and deathmay occur within 24 h after the administrationof a lethal dose Speck & Maaske, 1958 ; . Animals thatsurvivepoisoning recovercompletelywith no delayed or persistenteffect. Resistance of individual mutations. Therefore, the Leu79 ParC and Ile81 GyrA substitutions were introduced into susceptible pneumococcal strain R6 for the purpose of evaluating their contributions to fluoroquinolone resistance in an isogenic background and comparing them to Tyr and Phe substitutions at the same sites. Strains with single mutations in parC or gyrA. Transformation of R6 with PCR amplicons of QRDRs from parC and gyrA genes of clinical isolates containing mutations at Ser79 Ser81 hotspots Table 2 ; yielded six independent sets of transformants with low-level fluoroquinolone resistance. Transformants containing the ParC Ser79 substitutions were obtained at 4 10 with 1- g ml ciprofloxacin selection. Similarly, transformants containing the GyrA Ser81 substitutions were obtained at 1 10 with 0.032- g ml gemifloxacin selection. In contrast, mutation frequencies obtained in control experiments for parC and gyrA upon ciprofloxacin and gemifloxacin selection, respectively, were in the range of 10 8 and were significantly lower than transformation frequencies. Representative transformants OC 7451, OC 7452, and OC 7455 Table 3 ; , containing the Ser79 ParC Phe, Tyr, and Leu substitutions, and OC 7453, OC 7454, and OC 7456, containing the Ser81 GyrA Phe, Leu, and Ile substitutions were selected for further analysis. The results in Table 3 indicated that the MICs of the various tested fluoroquinolones against the single-substitution transformants were mostly allele independent. Thus, neither the Ser79Leu ParC OC 7455 ; nor the Ser81Ile GyrA substitution OC 7456 ; conferred lower fluoroquinolone susceptibilities than did the alternative Phe or Tyr substitutions. Indeed, OC 7456 had wild-type-like susceptibilities to both ciprofloxacin and levofloxacin. Generally, all Ser79 ParC and Ser81 GyrA substitutions decreased by twofold the susceptibilities of the transformants to levofloxacin, gemifloxacin, and gatifloxacin. However, for gatifloxacin the Ser81Tyr GyrA substitution produced a fourfold susceptibility decrease. For ciprofloxacin the ParC and GyrA substitutions produced fourfold and twofold decreases, respectively, whereas for both moxifloxacin and garenoxacin the decreases were twofold and fourfold and for norfloxacin were eightfold and zero, respectively. In addition to the Leu79 or Ile81 substitution, clinical iso and ginger. MODERATORS: Doc. sci.dr Emina Alimanovi- Halilovi, MODERATORS: dr. sci Vahid Jusufovi , dr i Raif Serdarevi, Mr. sci .dr. Huda Hajjirr, Dr. Bruno Abramusi, Mr. sci. dr Mirsad Ibisevi Prim.dr.Nedzmija Saracevi, mr i. dr. Samir anovi Emina Alimanovi Halilovi Thyroid ophthalmopathy etiology, corticosteroids and radiology therapy E. Alimanovi Halilovi, 1 S.E. Kuckali, 2 N. Obrali, 3 M. Alendar, 1 P. N. Sracevi 1. Eye Clinic, 2. Inst. for nuclear medicine, 3. Inst. for oncology, CC of Sarajevo Uni. Suzana Pavljasevi Alpha lipoic acid in optical nerve subatrophy treatment S. Pavljasevi, E. Tupkovi; Eye policlinic in Public Health Center Tuzla, Neurophysiology Department in Public Health Center Tuzla Emina Alimanovi Halilovi Diplopia as the first sign of meningeoma in the sella turcica space and posterior cranii cavity E. Alimanovi Halilovi, 1 J. Paladino, 2 Z. Heinrich, 3 N. orovi, 4 N. Al Hassan 1. Eye Clinic, 2. Cl. neurosurgery, 3. Gamma knife center Rebro, 4. Inst. for rehabilitation KCUS Miroslav Knezevi Hemangiomi orbite operisani tokom 2007 godine M. Knezevi, D. Rasi Klinicki Centar Srbije ocna klinika Suvad Karci Surgical treatment in the case of severe eye trauma to do or not to do S. Karci, H. Hajjir Eye Clinic Sarajevo Vahid Jusufovi Management of perforative eye wound with lens luxation in corpus vitreus V. Jusufovi, S. Canovi, V. Vukoti, Z. Musanovi Klinika za ocne bolesti, UKC Tuzla Samir anovi Modern aspects of ocular trauma according to eye perforative injury frequency in Tuzla Canton V. Jusufovi, Dz. Sarajli, M. Dizdarevi, H. Basi, S. Terzi Eye clinic, University Clinical Center in Tuzla, BiH Vahid Jusufovi Approach to operative careness of subtotal traumatic iridodialysis V. Jusufovi, S. Canovi , A. Pilavdzi, H. Basi UKC Tuzla and gemifloxacin.

In the formate form. The [ 3 H]IP, formed in the aortic slices was counted with a liquid scintillation counter and presented by disintegration per min DPM ; . The counts in DPM of two samples were averaged and the average DPMs of the blank values no slices present ; were subtracted to obtain the experimental data. Secondly, we determined the time course of the effects and ginkgo. Cal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents Chemother. 44: 31123117. Hiasa, H., and M. E. Shea. 2000. DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrasequinolone-DNA ternary complex. J. Biol. Chem. 275: 3478034786. Hooper, D. C. 1999. Mechanisms of quinolone resistance. Drug Resist. Updates 2: 3855. Hooper, D. C. 2000. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31: S24S28. Hooper, D. C. 2001. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32: S9S15. Ince, D., and D. C. Hooper. 2000. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drugtarget interactions. Antimicrob. Agents Chemother. 44: 33443350. Ince, D., and D. C. Hooper. 2001. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 27552764. Ito, H., H. Yoshida, M. Bogaki-Shonai, T. Niga, H. Hattori, and S. Nakamura. 1994. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother. 38: 20142023. Janoir, C., E. Varon, M. D. Kitzis, and L. Gutmann. 2001. New mutation in ParE in a pneumococcal in vitro mutant resistant to fluoroquinolones. Antimicrob. Agents Chemother. 45: 952955. Jones, R. N., M. A. Pfaller, and M. Stilwell. 2001. Activity and spectrum of BMS 284756, a new des-F 6 ; quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. Diagn. Microbiol. Infect. Dis. 39: 133135. Kaatz, G. W., and S. M. Seo. 1995. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39: 26502655. Khodursky, A. B., and N. R. Cozzarelli. 1998. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 273: 27668 27677. Lawrence, L. E., P. Wu, L. Fan, K. E. Gouveia, A. Card, M. Casperson, K. Denbleyker, and J. F. Barrett. 2001. The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J. Antimicrob. Chemother. 48: 195201. Lu, T., X. L. Zhao, and K. Drlica. 1999. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob. Agents Chemother. 43: 29692974. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1994. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38: 13451355. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship of the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40: 18811888. Novick, R. P. 1991. Genetic systems in staphylococci. Methods Enzymol. 204: 587636. Pan, X. S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41: 471474. Pan, X. S., and L. M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42: 28102816. Pan, X. S. and L. M. Fisher. 1999. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob. Agents Chemother. 43: 11291136.